LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial

• Published in: Pancreas Vol. 43; no. 8; p. 1223
• Main Authors: Steinberg, William M, Nauck, Michael A, Zinman, Bernard, Daniels, Gilbert H, Bergenstal, Richard M, Mann, Johannes F E, Steen Ravn, Lasse, Moses, Alan C, Stockner, Mette, Baeres, Florian M M, Marso, Steven P, Buse, John B
• Format: Journal Article
• Language: English
• Published: United States 01.11.2014
• Subjects: Acute Disease; Aged; Amylases - blood; Biomarkers; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - enzymology; Double-Blind Method; Fasting - blood; Female; Glucagon-Like Peptide 1 - adverse effects; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - pharmacology; Glucagon-Like Peptide 1 - therapeutic use; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Kidney - physiopathology; Lipase - blood; Liraglutide; Male; Middle Aged; Pancreatitis - chemically induced; Pancreatitis - etiology; Pancreatitis - prevention & control

This report from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial describes baseline lipase and amylase activity in type 2 diabetic subjects without acute pancreatitis symptoms before randomization to the glucagonlike peptide analog liragluti...